AnaptysBio, Inc.
US ˙ NasdaqGS ˙ US0327241065

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nicholas Lydon. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Nicholas Lydon has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:BPMC / Blueprint Medicines Corporation Director 58,026
US:ANAB / AnaptysBio, Inc. Director 6,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nicholas Lydon. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ANAB / AnaptysBio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANAB / AnaptysBio, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-01-31 ANAB Lydon Nicholas 16,666 15.0000 16,666 15.0000 249,990 358 116.91 1,698,432 679.40

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANAB / AnaptysBio, Inc. Insider Trades
Insider Sales ANAB / AnaptysBio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANAB / AnaptysBio, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANAB / AnaptysBio, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nicholas Lydon as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-06-14 2024-06-12 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,242 58,026 4.02
2023-06-23 2023-06-21 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,600 55,784 4.89
2022-06-30 2022-06-21 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,600 53,184 5.14
2022-05-25 2022-05-23 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
M - Exercise -10,909 0 -100.00
2022-05-25 2022-05-23 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 10,909 50,584 27.50 19.53 213,053 987,906
2021-06-04 2021-06-02 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 4,500 4,500
2021-06-04 2021-06-02 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,250 39,675 6.01
2020-10-05 2020-10-01 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -1,389 37,425 -3.58 92.06 -127,871 3,445,346
2020-10-05 2020-10-01 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -4,530 38,814 -10.45 92.88 -420,746 3,605,044
2020-10-05 2020-10-01 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -3,896 43,344 -8.25 93.68 -364,977 4,060,466
2020-09-21 2020-09-17 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -500 47,240 -1.05 80.00 -40,000 3,779,200
2020-07-08 2020-07-06 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -600 47,740 -1.24 81.02 -48,612 3,867,895
2020-07-08 2020-07-06 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -25,407 48,340 -34.45 80.44 -2,043,739 3,888,470
2020-07-06 2020-07-02 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -2,825 73,747 -3.69 80.13 -226,367 5,909,347
2020-07-06 2020-07-01 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -1,300 76,572 -1.67 80.21 -104,273 6,141,840
2020-06-26 2020-06-24 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 4,500 4,500
2020-06-26 2020-06-24 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,250 77,872 2.98
2020-06-25 2020-06-23 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -400 75,622 -0.53 80.00 -32,000 6,049,760
2020-06-23 2020-06-22 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -13,017 76,022 -14.62 80.29 -1,045,135 6,103,806
2020-06-23 2020-06-19 4 BPMC Blueprint Medicines Corp
Restricted Stock Units
M - Exercise -1,312 0 -100.00
2020-06-23 2020-06-19 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 1,312 89,039 1.50
2020-05-19 2020-05-15 4 BPMC Blueprint Medicines Corp
Common Stock
G - Gift -20,000 87,727 -18.57
2019-08-21 2019-08-19 4 BPMC Blueprint Medicines Corp
Common Stock
G - Gift -20,000 107,727 -15.66
2019-06-20 2019-06-19 4 BPMC Blueprint Medicines Corp
Restricted Stock Units
A - Award 1,312 1,312
2019-06-20 2019-06-19 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 4,875 4,875
2019-06-17 2019-06-13 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -25,000 127,727 -16.37 90.36 -2,259,000 11,541,412
2019-06-14 2019-06-12 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -300 152,727 -0.20 81.96 -24,588 12,517,505
2019-06-14 2019-06-12 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -2,000 153,027 -1.29 82.45 -164,900 12,617,076
2019-06-14 2019-06-12 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -5,200 155,027 -3.25 83.83 -435,916 12,995,913
2019-06-14 2019-06-12 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -6,300 160,227 -3.78 84.66 -533,358 13,564,818
2019-06-14 2019-06-12 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -11,200 166,527 -6.30 85.75 -960,400 14,279,690
2019-02-11 2019-02-08 4 ANAB ANAPTYSBIO INC
Director Stock Option (Right to Buy)
A - Award 6,000 6,000
2018-06-25 2018-06-21 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 7,500 29,318 34.38
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -2,222 271,106 -0.81 90.26 -200,549 24,468,970
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -2,803 273,328 -1.02 89.42 -250,631 24,439,732
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -4,250 276,131 -1.52 88.30 -375,267 24,381,870
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -9,425 280,381 -3.25 87.46 -824,341 24,523,019
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -1,390 289,806 -0.48 86.15 -119,753 24,967,714
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -10,310 291,196 -3.42 85.11 -877,491 24,783,895
2018-04-18 2018-04-16 4 ANAB ANAPTYSBIO INC
Common Stock
S - Sale X -2,600 301,506 -0.85 84.18 -218,880 25,382,162
2018-03-02 2018-02-28 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -4,613 177,727 -2.53 86.35 -398,333 15,346,726
2018-03-02 2018-02-28 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -5,527 182,340 -2.94 86.92 -480,407 15,848,993
2018-03-02 2018-02-28 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -5,264 187,867 -2.73 88.20 -464,285 16,569,869
2018-03-02 2018-02-28 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -9,596 193,131 -4.73 89.03 -854,332 17,194,453
2018-02-20 2018-02-15 4 ANAB ANAPTYSBIO INC
Series C Preferred Stock Warrant (right to buy)
M - Exercise -16,483 0 -100.00
2018-02-20 2018-02-15 4 ANAB ANAPTYSBIO INC
Common Stock
M - Exercise 16,483 304,106 5.73 4.55 74,998 1,383,682
2018-02-06 2018-02-02 4 ANAB ANAPTYSBIO INC
Director Stock Option (right to buy)
A - Award 6,000 6,000
2017-06-23 2017-06-21 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 10,909 21,818 100.00
2017-03-16 2017-03-14 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -1,400 202,727 -0.69 39.72 -55,608 8,052,316
2017-03-16 2017-03-14 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale X -68,600 204,127 -25.15 40.06 -2,748,116 8,177,328
2017-02-28 2017-02-24 4 ANAB ANAPTYSBIO INC
Director Stock Option (right to buy)
A - Award 15,000 15,000
2017-01-31 2017-01-31 4 ANAB ANAPTYSBIO INC
Series D Preferred Stock
C - Conversion -67,345 0 -100.00
2017-01-31 2017-01-31 4 ANAB ANAPTYSBIO INC
Series C Preferred Stock
C - Conversion -55,403 0 -100.00
2017-01-31 2017-01-31 4 ANAB ANAPTYSBIO INC
Series B Preferred Stock
C - Conversion -80,877 0 -100.00
2017-01-31 2017-01-31 4 ANAB ANAPTYSBIO INC
Common Stock
P - Purchase 16,666 287,623 6.15 15.00 249,990 4,314,345
2017-01-31 2017-01-31 4 ANAB ANAPTYSBIO INC
Common Stock
C - Conversion 203,625 270,957 302.42
2017-01-25 3 ANAB ANAPTYSBIO INC
Common Stock
134,664
2017-01-25 3 ANAB ANAPTYSBIO INC
Common Stock
134,664
2016-06-27 2016-06-23 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 10,909 10,909
2015-04-30 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-30 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)